EC Number   |
Application |
Reference |
|---|
   3.4.21.34 | medicine |
DX-88 has a strong neuroprotective effect in the early phases of brain ischemia preventing reperfusion injury and indicates that inhibition of plasma kallikrein may be useful tool in the strategy aimed at reducing the detrimental effects linked to reperfusion |
670001 |
| 3.4.21.34 | medicine |
enzyme inhibition can decrease blood-brain barrier damage and cell invasion during neuroinflammation and may offer a strategy for the treatment of multiple sclerosis |
755272 |
| 3.4.21.34 | medicine |
porcine pancreatic kallikrein is absorbed after oral administration and to exert its pharmacological action via kinins produced by kininogen degradation in dogs |
717318 |
| 3.4.21.34 | medicine |
targeting plasma kallikrein may offer a strategy for prevention or treatment of thrombosis |
732928 |
| 3.4.21.34 | pharmacology |
design of specific inhibitors for proteases like plasma kallikrein, but not protein C, to diminish the complement hydrolysis and coagulation during sepsis |
653796 |
